Free press releases distribution network?

Agency / Source: Frost & Sullivan

Check Ads Availability|e-mail Article


Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!



Market for POC Molecular Tests Boosted by Discovery of New Disease Markers - As developers of point of care (POC) molecular tests enhance their application scope to detect new disease markers, the POC molecular diagnostics market will present attractive opportunities
Market for POC Molecular Tests Boosted by Discovery of New Disease Markers

 

PRZOOM - /newswire/ - London, United Kingdom, 2008/04/14 - As developers of point of care (POC) molecular tests enhance their application scope to detect new disease markers, the POC molecular diagnostics market will present attractive opportunities.

   
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Market participants can enhance the utilization of POC molecular tests by improvising the existing tests and simultaneously focusing on R&D to develop innovative ways of detecting new disease markers.

New analysis from Frost & Sullivan (drugdiscoverytechnologies.frost.com), finds that The Emerging European Molecular POC Testing Markets are dominated by tests for infectious agents detection, especially for sexually transmitted diseases.

If you are interested in a virtual brochure, which provides manufacturers, end users and other industry participants with an overview of the emerging European molecular POC testing markets, then send an email to Patrick Cairns, Corporate Communications, at pcairns_pr[.]frost.com, your full name, company name, title, telephone number, company email address, company website, city, state and country. Upon receipt of the above information, an overview will be sent to you by email.

"The industry and academia should collaborate to research new disease markers and market them efficiently," says Frost & Sullivan Research Analyst Gayathry Ramachandran. "Campaigns and awareness programs must be conducted to educate patients and healthcare professionals regarding the benefits of POC tests for infectious disease detection."

The outlook of infectious disease diagnostics will change drastically with the adoption of POC molecular techniques. Infectious disease POC testing is gradually picking up steam, especially as medical authorities are working towards reducing the occurrence and recurrence of these diseases.

Early diagnosis of infectious agents is crucial to reduce the spread and recurrence of infection. By enabling on-the-spot detection of the disease, POC diagnostics facilitates the design of an appropriate treatment at the earliest.

"After the success of HIV testing in POC format, the platform is being increasingly used to detect other sexually transmitted diseases such as chlamydia and gonorrhoeae," notes Ramachandran. "The adoption of these tests at screening centres, community clinics and other decentralised settings will accelerate the growth of POC infectious disease testing."

However, to gain widespread acceptance in the infectious disease segment, molecular POC test companies should enhance patients' awareness of the solution and wean them away from traditional nucleic acid testing in the laboratories. They should also gain healthcare professionals' confidence to widen the base of POC infectious disease testing.

While companies focus on marketing, researchers and universities have been concentrating on developing polymer disposable chips that can perform multiparametric tests at the POC level. This will be a cost-effective solution for the detection of infectious disease agents.

The introduction of additional POC tests for infectious disease detection will facilitate the screening of fatal diseases at public health centres. Market entrants will do well to be aware of this opportunity and introduce relevant technologies and skills into the market.

The Emerging European Molecular POC Testing Markets is part of the Drug Discovery Technologies Growth Partnership Service programme, which also includes research in the following markets: European Molecular Diagnostics Markets, European IVD Market, European Cancer Diagnostic Market and European Primary Care Diagnostics. All research services included in subscriptions provide detailed market opportunities and industry trends that have been evaluated following extensive interviews with market participants. Interviews with the press are available.

Frost & Sullivan, the Global Growth Consulting Company, partners with clients to accelerate their growth. The company's Growth Partnership Services, Growth Consulting and Career Best Practices empower clients to create a growth focused culture that generates, evaluates and implements effective growth strategies. Frost & Sullivan employs over 45 years of experience in partnering with Global 1000 companies, emerging businesses and the investment community from more than 30 offices on six continents.

The Emerging European Molecular POC Testing Markets M1F3

 
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Agency / Source: Frost & Sullivan

 
 

Availability: All Regions (Including Int'l)

 

Traffic Booster: [/] Quick PRZOOM - Press & Newswire Visibility Checker

 

Distribution / Indexing: [+] / [Company listed above is a registered member of our network. Content made possible by PRZOOM / PRTODAY indexing services]

 
 
# # #
 

 
  Your Banner Ad showing on ALL
Pharma/BioTech/Nutrition articles,
CATCH Visitors via Your Competitors Announcements!


Market for POC Molecular Tests Boosted by Discovery of New Disease Markers

Company website links NOT available to basic submissions
It is OK to republish and/or LINK any newswire for any legitimate media purpose as long as you name PRZOOM - Press & Newswire and LINK as the source.
 
  For more information, please visit:
Is this your article? Activate ALL web links by Upgrading to Press Release PREMIUM Plan Now!
Frost & Sullivan |
Contact: Patrick Cairns 
+27 18 468 2315 patrick.cairns[.]frost.com
 
PRZOOM / PRTODAY - Newswire Today disclaims any content contained in this article. If you need/wish to contact the company who published the current release, you will need to contact them - NOT us. Issuers of articles are solely responsible for the accuracy of their content. Our complete disclaimer appears here.
IMPORTANT INFORMATION: Issuance, publication or distribution of this press release in certain jurisdictions could be subject to restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with the applicable rules and regulations in the particular jurisdiction. This press release does not constitute an offer or an offering to acquire or subscribe for any Frost & Sullivan securities in any jurisdiction including any other companies listed or named in this release.

Pharma/BioTech/Nutrition via RSSAdd NewswireToday - PRZOOM Headline News to FeedBurner
Find who RetweetFollow @NewswireTODAY



Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!




Read Latest Press Releases From Frost & Sullivan / Company Profile


Read Pharma/BioTech/Nutrition Most Recent Related Press Releases:

Frost & Sullivan Commends Nemaura for Developing Superior Transdermal Drug Delivery Technology Platforms, the Memspatch and Micropatch
Greenphire Sponsors Second Annual Clinical Trial Agreements, Investigator Payments and Fair Market Value Meeting
Genentech’s Gazyva Helped People with Previously Untreated Follicular Lymphoma Live Significantly Longer
BD Announces Adoption of Windows 10 ‘Internet of Things’ for the Pyxis™ ES System
Greenphire Named to Deloitte 2016 Technology Fast 500™
Genentech Showcases New Clinical Data Across a Variety of Blood Diseases at American Society of Hematology 2016 Annual Meeting
BD Collaborates with JDRF to Focus on Extended Wear Innovations for Insulin Infusion Delivery
BD Launches First Syringe Designed for Use with Humulin® R U-500 Insulin
MDxHealth Announces Unique CPT Code Awarded for ConfirmMDx from the American Medical Association
BD MAX™ Vaginal Panel Receives FDA Market Authorization to Detect Most Common Causes of Vaginal Infections

Boost Your Social Network
& Crowdfunding Campaigns


LIFETIME SOCIAL MEDIA WALL
 
NewswireToday Celebrates 10 Years in Business
Find business coaching, life coaching, executive coaching and corporate coaching, best selling coaching books, ...



PREMIUM Members


Visit  Triggr & Bloom

Visit  JobsWare.com

Visit  La Bella Bakery Artisan Bakery Arizona







 
  ©2016 PRZOOM — Limelon Advertising, Co.
Home | About PRZOOM | Advertise/Pricing | Contact | Investors | Privacy/TOS | Sitemap | FRANCAIS
newswire, PR free press releases distribution service magazines engine news alert newsroom press room breaking news public relations articles company news alerts newswiredistribution ezine bizentrepreneur biznewstoday digital business report market search pr firms agencies reports distri-bution today investor relation successful internet entrepreneur newswire distribution prtoday.com freenewswiredistribution asianewstoday bizwiretoday USA pr UK today